Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06482554 · ClinicalTrials.gov registry record · Phase 3
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
A Phase 3 study of Schizophrenia and Apathy, sponsored by Louisiana State University Health Sciences Center Shreveport.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06482554 is a Phase 3 study of Schizophrenia and Apathy that is actively recruiting participants, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 80 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06482554, a Phase 3 study of Schizophrenia and Apathy, is actively recruiting participants, sponsored by Louisiana State University Health Sciences Center Shreveport.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvement in apathy scores and changes in elements of the PANSS (Positive and Negative Syndrome Scale) due to treatment with Lumateperone.
Conditions Studied
Interventions
- DRUG Lumateperone 42 mg
- DRUG Risperidone 2 mg
Study Locations (1)
Louisiana
- LSU Health Shreveport - Shreveport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06482554
The ClinicalTrials.gov registry entry for NCT06482554 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The listed sponsor is Louisiana State University Health Sciences Center Shreveport, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Lumateperone 42 mg is the first listed.
NCT06482554 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT06482554 about?
NCT06482554 is a clinical study titled "Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.". This study is looking to determine if Lumateperone improves motivation in patients with schizophrenia or schizoaffective disorders who show high levels of apathy as judged by AES-C-Apathy (Apathy Evaluation Scale - Clinician - Apathy) assessment and to examine a possible correlation between improvem...
What is the current status of trial NCT06482554?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2024-06. Estimated completion is 2026-12.
What conditions does trial NCT06482554 study?
This clinical trial studies the following conditions: Schizophrenia, Apathy, Schizophrenia; Psychosis.
What interventions are being tested in trial NCT06482554?
The interventions under investigation include: Lumateperone 42 mg (DRUG), Risperidone 2 mg (DRUG).
Who is sponsoring clinical trial NCT06482554?
This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06482554 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.